September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Optical coherence tomography angiography in inactive type 2 neovascularization undergoing monthly anti-VEGF treatment
Author Affiliations & Notes
  • Fabio Scarinci
    Ophthalmology, Fondazione G.B. Bietti -IRCCS-, Rome , Italy
  • Maria Cristina Parravano
    Ophthalmology, Fondazione G.B. Bietti -IRCCS-, Rome , Italy
  • Lea Querques
    Ophthalmology, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele , Milano , Italy
    Ophthalmology, Fondazione G.B. Bietti -IRCCS-, Rome , Italy
  • Daniele De Geronimo
    Ophthalmology, Fondazione G.B. Bietti -IRCCS-, Rome , Italy
  • Paola Giorno
    Ophthalmology, Fondazione G.B. Bietti -IRCCS-, Rome , Italy
  • Monica Varano
    Ophthalmology, Fondazione G.B. Bietti -IRCCS-, Rome , Italy
  • Francesco Bandello
    Ophthalmology, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele , Milano , Italy
  • Giuseppe Querques
    Ophthalmology, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele , Milano , Italy
  • Footnotes
    Commercial Relationships   Fabio Scarinci, None; Maria Cristina Parravano, None; Lea Querques, None; Daniele De Geronimo, None; Paola Giorno, None; Monica Varano, None; Francesco Bandello, None; Giuseppe Querques, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 56. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Fabio Scarinci, Maria Cristina Parravano, Lea Querques, Daniele De Geronimo, Paola Giorno, Monica Varano, Francesco Bandello, Giuseppe Querques; Optical coherence tomography angiography in inactive type 2 neovascularization undergoing monthly anti-VEGF treatment. Invest. Ophthalmol. Vis. Sci. 2016;57(12):56.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To characterize the quantitative and qualitative changes of inactive type 2 Choroidal Neovascolarization (CNV) by means of Optical Coherence Tomography Angiography (OCTA), in eyes undergoing monthly ranibizumab injections for neovascular age related macular degeneration (nAMD).

Methods : Fourteen consecutive patients with nAMD treated with monthly ranibizumab injections were prospectively enrolled. At each month, ophthalmologic evaluation included: visual acuity (ETDRS charts) measurement, fundus biomicroscopy, and Spectral Domain-Optical Coherence Tomography (SD-OCT) B-scan. OCTA (3X3 mm and 6x6 mm macular cube images) was also performed after the loading phase (three injections). All nAMD eyes, showing neither intra nor subretinal fluid on B-scan SD-OCT for 3 consecutive monthly visits after the loading phase, were considered as inactive and their CNV area on OCTA images was manually delineated (baseline examination) using ImageJ software (United States of National Institutes of Health).

Results : Twelve eyes of 12 patients (5 Female/ 7 Male; mean age 75.6+/-9.4 years) showing inactive CNV were considered for the analysis. Two out of 12 eyes were excluded because of presence of low-quality images due to instability of fixation. All eyes included were diagnosed with type 2 CNV. Mean duration of symptoms at time of diagnosis was 30.2+/- 27.1 days, and mean size of CNV at FA was 5.65+/-10.35 mm2. Mean time from CNV diagnosis to the lesion being inactive was 3.9 months with an average of 3.9 intravitreal injections. Quantitative OCTA analysis revealed a CNV area of 4.99+/-3.99 mm2 at baseline examination, which did not change significantly (5.15+/-4.27 mm2; p=0.99) during the follow up. Qualitative OCTA analysis revealed the persistent visualization of the main neovascular complex in 90% of the eyes. However, a subtle shrinkage of vessels at the edge of the lesion and reduction of the fine capillary network within the neovascular lesion was observed in all eyes. (Figure 1)

Conclusions : We demonstrated that type 2 CNVs were still visible on OCTA despite continuous anti-VEGF administration and monthly intravitreal injections of ranibizumab did not affect the size of inactive CNV.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×